Compare XXII & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XXII | NVNO |
|---|---|---|
| Founded | 1998 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 7.3M |
| IPO Year | N/A | N/A |
| Metric | XXII | NVNO |
|---|---|---|
| Price | $0.80 | $10.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 155.4K | 18.9K |
| Earning Date | 11-04-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,346,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $79.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.98 | N/A |
| 52 Week Low | $0.75 | $10.54 |
| 52 Week High | $140.92 | $196.70 |
| Indicator | XXII | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 40.68 | 91.62 |
| Support Level | $0.81 | $0.31 |
| Resistance Level | $0.89 | $12.79 |
| Average True Range (ATR) | 0.07 | 0.31 |
| MACD | 0.00 | 1.09 |
| Stochastic Oscillator | 26.17 | 84.14 |
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.